SCHEMBL4013466

SCHEMBL4013466

CCCN(CC1CC1)C(=O)Cn1nc(C(=O)C(C)(CC)CC)c2ccc(OC)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.38
CRHR1 P34998 3/20 0.37
HTR3A P46098 1/20 0.35
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 2/20 0.35
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP13 P45452 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CFD P00746 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CNR2 P34972 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5173620 0.93 MLYCD (0.39) MLYCDCRHR1HTR3AALDH1A1KMT2A
SCHEMBL3955748 0.86 HTR3A (0.38) MLYCDCRHR1HTR3AALDH1A1KMT2A
SCHEMBL4014428 0.82 HTR3A (0.38) HTR3ACNR2NPC1
SCHEMBL4012899 0.80 CNR2 (0.38) ALDH1A1MAPTLMNAKDM4ECNR2
SCHEMBL13848579 0.80 CFD (0.40) MLYCDCRHR1ALDH1A1CFDCNR2
SCHEMBL13844140 0.79 HTR3A (0.41) HTR3AMAPTCFDCNR2
SCHEMBL13844148 0.78 CNR2 (0.41) HTR3AKMT2AMAPTCFDCNR2
SCHEMBL4015275 0.78 CNR2 (0.39) ALDH1A1MAPTLMNAKDM4ECNR2
SCHEMBL3960137 0.76 ATM (0.38) HTR3AALDH1A1MAPTCFDKDM4E
SCHEMBL3951267 0.75 TSPO (0.38) HTR3AALDH1A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528163-B2 N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye MERCK & CO. INC. (US) 2009-05-05 US disclosed
US-20060020000-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020000-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNH3, KCNJ11 MLYCD 4279/4885CRHR1 2458/4885HTR3A 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.